Premium
Oxazepam pharmacokinetics in patients with epilepsy treated long‐term with phenytoin alone or in combination with phenobarbitone.
Author(s) -
Scott AK,
Khir AS,
Steele WH,
Hawksworth GM,
Petrie JC
Publication year - 1983
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1983.tb02193.x
Subject(s) - oxazepam , phenytoin , pharmacokinetics , glucuronidation , phenobarbital , pharmacology , epilepsy , anticonvulsant , medicine , chemistry , drug , bilirubin , endocrinology , benzodiazepine , microsome , enzyme , biochemistry , receptor , psychiatry
The pharmacokinetics and serum protein binding of oxazepam, a drug mainly eliminated by a single step glucuronidation reaction, were studied in nine epileptic patients treated long‐term with phenytoin or phenytoin with phenobarbitone, and in nine healthy control subjects. Oxazepam elimination half‐life was shorter and apparent oral clearance higher in treated patients than in age and sex matched control subjects. Serum bilirubin concentration was lower in treated patients. There was no significant correlation between serum bilirubin concentrations and oxazepam elimination. Serum alpha 1‐acid glycoprotein concentration was higher in the treated patients than in the control group. Oxazepam was more than 93% bound to serum proteins, but the extent of binding was not significantly different between the two groups. These results show that oxazepam glucuronyl transferase activity is increased by treatment with phenytoin alone or in combination with phenobarbitone in epileptic patients.